Anyone here have any views on the prospects for GSK's platelet booster Promacta?
GSK has it in two Phase III trials as an add-on to Pegasys/Pegintron + Ribavirin in HCV. Phase II data showed a substantial increase in number of patients completing therapy (claim is 65% vs 6%).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.